Are you seeking a robust, specific, and fast characterization of Complement-dependent cytotoxicity (CDC) response for your therapeutic antibodies? Look no further!
Introducing our assay-ready solution, designed to accurately detect cell lysis triggered by CDC. We are excited to offer the iLite® CDC bioassay, which provides unmatched adaptability for assessing Ab-induced CDC response and CDC inhibition by complement-targeted therapeutics.
The assay presents great customization possibilities to generate a cell line with your surface antigens of interest, allowing you to pinpoint the Mechamis of Action (MoA).
Our CDC bioassay is a game-changing solution to streamline your antibody characterization or complement target therapeutic.